{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:58:30Z","timestamp":1789721910214,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.otc.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T07:47:11Z","timestamp":1623311231000},"page":"803-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Biologics for Immune-Mediated Sensorineural Hearing Loss"],"prefix":"10.1016","volume":"54","author":[{"given":"Andrea","family":"Vambutas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella V.","family":"Davia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.otc.2021.05.005_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/000348947908800501","article-title":"Autoimmune sensorineural hearing loss","volume":"88","author":"McCabe","year":"1979","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"9","key":"10.1016\/j.otc.2021.05.005_bib2","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1172\/JCI76503","article-title":"Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease","volume":"124","author":"Vambutas","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.otc.2021.05.005_bib3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.semarthrit.2004.07.001","article-title":"Immune mediated inner ear disease: 10-year experience","volume":"34","author":"Broughton","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.otc.2021.05.005_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1288\/00005537-198803000-00001","article-title":"Clinical diagnosis of immune inner-ear disease","volume":"98","author":"Hughes","year":"1988","journal-title":"Laryngoscope"},{"key":"10.1016\/j.otc.2021.05.005_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fneur.2016.00182","article-title":"Clinical subgroups in bilateral Meniere disease","volume":"7","author":"Frejo","year":"2016","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.otc.2021.05.005_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1044\/2014_AJA-13-0060","article-title":"Higher prevalence of autoimmune diseases and longer spells of vertigo in patients affected with familial Meniere's disease: a clinical comparison of familial and sporadic Meniere's disease","volume":"23","author":"Hietikko","year":"2014","journal-title":"Am J Audiol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2012.07.027","article-title":"Biologic drugs in autoinflammatory syndromes","volume":"12","author":"Caorsi","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.otc.2021.05.005_bib8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","article-title":"Autoinflammatory disease reloaded: a clinical perspective","volume":"140","author":"Kastner","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2133.1979.tb03572.x","article-title":"The \u2018Muckle-Wells\u2019 syndrome","volume":"100","author":"Muckle","year":"1979","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.005_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","article-title":"NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder","volume":"20","author":"Agostini","year":"2004","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12016-013-8406-7","article-title":"Cogan's syndrome\u2013clinical guidelines and novel therapeutic approaches","volume":"47","author":"Tayer-Shifman","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.otc.2021.05.005_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/lio2.28","article-title":"AAO: autoimmune and autoinflammatory (disease) in otology: what is new in immune-mediated hearing loss","volume":"1","author":"Vambutas","year":"2016","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"10","key":"10.1016\/j.otc.2021.05.005_bib13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/archotol.1995.01890100075013","article-title":"Serum antibodies to heat shock protein 70 in sensorineural hearing loss","volume":"121","author":"Bloch","year":"1995","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.otc.2021.05.005_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5955(97)00198-6","article-title":"Failure of elevated heat shock protein 70 antibodies to alter cochlear function in mice","volume":"116","author":"Trune","year":"1998","journal-title":"Hear Res"},{"issue":"3","key":"10.1016\/j.otc.2021.05.005_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2249.2006.03227.x","article-title":"Antibody reactivity to heat shock protein 70 and inner ear-specific proteins in patients with idiopathic sensorineural hearing loss","volume":"146","author":"Tebo","year":"2006","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.otc.2021.05.005_bib16","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.4049\/jimmunol.177.6.4203","article-title":"Increased frequencies of cochlin-specific T\u00a0cells in patients with autoimmune sensorineural hearing loss","volume":"177","author":"Baek","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.otc.2021.05.005_bib17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s10875-013-9926-x","article-title":"Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease","volume":"33","author":"Pathak","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"issue":"7","key":"10.1016\/j.otc.2021.05.005_bib18","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s10875-013-9926-x","article-title":"Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease","volume":"33","author":"Pathak","year":"2013","journal-title":"J Clin Immunol"},{"issue":"12","key":"10.1016\/j.otc.2021.05.005_bib19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archotol.1980.00790360050013","article-title":"The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study","volume":"106","author":"Wilson","year":"1980","journal-title":"Arch Otolaryngol"},{"issue":"5 Pt 1","key":"10.1016\/j.otc.2021.05.005_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1288\/00005537-198405000-00016","article-title":"Steroid use in idiopathic sudden sensorineural hearing loss","volume":"94","author":"Moskowitz","year":"1984","journal-title":"Laryngoscope"},{"issue":"4 Pt 1","key":"10.1016\/j.otc.2021.05.005_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/000348947708600406","article-title":"Natural history of sudden sensorineural hearing loss","volume":"86","author":"Mattox","year":"1977","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"10.1016\/j.otc.2021.05.005_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/00129492-200309000-00006","article-title":"Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis","volume":"24","author":"Chen","year":"2003","journal-title":"Otol Neurotol"},{"issue":"20","key":"10.1016\/j.otc.2021.05.005_bib23","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1001\/jama.2011.679","article-title":"Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial","volume":"305","author":"Rauch","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.otc.2021.05.005_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MAO.0b013e318168da7a","article-title":"Combination therapy (intratympanic dexamethasone\u00a0+ high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss","volume":"29","author":"Battaglia","year":"2008","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/j.otc.2021.05.005_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/MAO.0000000000000450","article-title":"A\u00a0prospective, multi-centered study of the treatment of idiopathic sudden sensorineural hearing loss with combination therapy versus high-dose prednisone alone: a 139 patient follow-up","volume":"35","author":"Battaglia","year":"2014","journal-title":"Otol Neurotol"},{"issue":"5","key":"10.1016\/j.otc.2021.05.005_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.mao.0000185081.28598.5c","article-title":"Serial audiometry in a clinical trial of AIED treatment","volume":"26","author":"Niparko","year":"2005","journal-title":"Otol Neurotol"},{"issue":"1\u20132","key":"10.1016\/j.otc.2021.05.005_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(02)00190-X","article-title":"Interferon-gamma production to inner ear antigens by T\u00a0cells from patients with autoimmune sensorineural hearing loss","volume":"130","author":"Lorenz","year":"2002","journal-title":"J\u00a0Neuroimmunol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1086\/302461","article-title":"A\u00a0gene for fluctuating, progressive autosomal dominant nonsyndromic hearing loss, DFNA16, maps to chromosome 2q23-24.3","volume":"65","author":"Fukushima","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.otc.2021.05.005_bib29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1097\/00005537-200311000-00008","article-title":"Intratympanic steroids: do they acutely improve hearing in cases of cochlear hydrops?","volume":"113","author":"Hillman","year":"2003","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.otc.2021.05.005_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/00016489.2016.1224920","article-title":"Repeated courses of intratympanic dexamethasone injection are effective for intractable Meniere's disease","volume":"137","author":"Leng","year":"2017","journal-title":"Acta Otolaryngol"},{"issue":"11","key":"10.1016\/j.otc.2021.05.005_bib31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/2013.jamaoto.76","article-title":"Diagnostic and prognostic utility of measuring tumor necrosis factor in the peripheral circulation of patients with immune-mediated sensorineural hearing loss","volume":"138","author":"Svrakic","year":"2012","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A\u00a0practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.otc.2021.05.005_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.21179","article-title":"Etanercept therapy for immune-mediated cochleovestibular disorders: a multicenter, open-label, pilot study","volume":"53","author":"Matteson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.otc.2021.05.005_bib34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.mao.0000185082.28598.87","article-title":"Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study","volume":"26","author":"Cohen","year":"2005","journal-title":"Otol Neurotol"},{"issue":"9","key":"10.1016\/j.otc.2021.05.005_bib35","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/00005537-200209000-00019","article-title":"Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation","volume":"112","author":"Satoh","year":"2002","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.otc.2021.05.005_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000095897","article-title":"Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss","volume":"11","author":"Van Wijk","year":"2006","journal-title":"Audiol Neurootol"},{"issue":"9","key":"10.1016\/j.otc.2021.05.005_bib37","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/MAO.0000000000000566","article-title":"An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease","volume":"35","author":"Derebery","year":"2014","journal-title":"Otol Neurotol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.005_bib38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.1780240308","article-title":"Successful treatment of sudden hearing loss in Cogan's syndrome with corticosteroids","volume":"24","author":"Haynes","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.otc.2021.05.005_bib39","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.3899\/jrheum.080203","article-title":"Efficacy of infliximab in Cogan's syndrome","volume":"35","author":"Ghadban","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.otc.2021.05.005_bib40","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/art.21807","article-title":"Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra","volume":"54","author":"Mirault","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12969-015-0041-9","article-title":"Early detection of sensorineural hearing loss in Muckle-Wells-syndrome","volume":"13","author":"Kuemmerle-Deschner","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"10.1016\/j.otc.2021.05.005_bib42","doi-asserted-by":"crossref","first-page":"e5293","DOI":"10.1371\/journal.pone.0005293","article-title":"Alternate splicing of interleukin-1 receptor type II (IL1R2) in\u00a0vitro correlates with clinical glucocorticoid responsiveness in patients with AIED","volume":"4","author":"Vambutas","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.otc.2021.05.005_bib43","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.4049\/jimmunol.1002275","article-title":"IL-1beta is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease","volume":"186","author":"Pathak","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.otc.2021.05.005_bib44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"14","key":"10.1016\/j.otc.2021.05.005_bib45","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.290.14.1875","article-title":"Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial","volume":"290","author":"Harris","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.otc.2021.05.005_bib46","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/ard.2009.118307","article-title":"Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission","volume":"69","author":"Kuriya","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.otc.2021.05.005_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00005537-200003000-00024","article-title":"Characterization of an experimentally induced inner ear immune response","volume":"110","author":"Ma","year":"2000","journal-title":"Laryngoscope"},{"issue":"12","key":"10.1016\/j.otc.2021.05.005_bib48","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1097\/MLG.0b013e3181461f92","article-title":"AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis","volume":"117","author":"Barkdull","year":"2007","journal-title":"Laryngoscope"},{"issue":"8","key":"10.1016\/j.otc.2021.05.005_bib49","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/MAO.0000000000000466","article-title":"Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study","volume":"35","author":"Suckfuell","year":"2014","journal-title":"Otol Neurotol"},{"issue":"5","key":"10.1016\/j.otc.2021.05.005_bib50","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/MAO.0000000000002229","article-title":"Efficacy and safety of AM-111 in the treatment of acute unilateral sudden deafness-a double-blind, randomized, placebo-controlled phase 3 study","volume":"40","author":"Staecker","year":"2019","journal-title":"Otol Neurotol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0162-3109(93)90062-U","article-title":"Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines","volume":"26","author":"Nagy","year":"1993","journal-title":"Immunopharmacology"},{"issue":"Suppl 1","key":"10.1016\/j.otc.2021.05.005_bib52","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1191\/0961203305LU2109OA","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.otc.2021.05.005_bib53","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijporl.2009.06.025","article-title":"Mycophenolate mofetil as a treatment of steroid dependent Cogan's syndrome in childhood","volume":"73","author":"Hautefort","year":"2009","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"6","key":"10.1016\/j.otc.2021.05.005_bib54","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajmg.a.32685","article-title":"Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature","volume":"149A","author":"Anderka","year":"2009","journal-title":"Am J Med Genet A"},{"issue":"4","key":"10.1016\/j.otc.2021.05.005_bib55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00016489.2011.647359","article-title":"L-N-Acetylcysteine treatment is associated with improved hearing outcome in sudden idiopathic sensorineural hearing loss","volume":"132","author":"Angeli","year":"2012","journal-title":"Acta Otolaryngol"},{"issue":"1\u20133","key":"10.1016\/j.otc.2021.05.005_bib56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12026-015-8696-3","article-title":"N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients","volume":"63","author":"Pathak","year":"2015","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.otc.2021.05.005_bib57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/00016489.2016.1214981","article-title":"N-acetylcysteine as a single therapy for sudden deafness","volume":"137","author":"Chen","year":"2016","journal-title":"Acta Otolaryngol"},{"issue":"4","key":"10.1016\/j.otc.2021.05.005_bib58","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000320606","article-title":"A\u00a0pilot study of rituximab in immune-mediated inner ear disease","volume":"16","author":"Cohen","year":"2011","journal-title":"Audiol Neurootol"},{"issue":"2","key":"10.1016\/j.otc.2021.05.005_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0272-2712(18)30690-5","article-title":"Autoimmunity and otologic disease: clinical and experimental aspects","volume":"8","author":"Barna","year":"1988","journal-title":"Clin Lab Med"},{"issue":"3","key":"10.1016\/j.otc.2021.05.005_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2125.2006.02617.x","article-title":"Rare diseases and orphan drugs","volume":"61","author":"Aronson","year":"2006","journal-title":"Br J Clin Pharmacol"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:52:42Z","timestamp":1710503562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666521000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0030666521000852"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2021.05.005","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for Immune-Mediated Sensorineural Hearing Loss","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}